Optimal Balance Pharmacy, a compounding pharmacy based in Houston, Texas, has initiated a voluntary nationwide recall of one lot of its Compounded Glutathione 200 mg/mL 30 mL multi‑dose vials at the patient level, according to a safety notice posted by the U.S. Food and Drug Administration (FDA).
The recall, announced in an FDA release dated August 19, 2026, applies to a specific lot of the injectable glutathione product. The FDA notice states that the recall is voluntary and nationwide, meaning it covers all U.S. locations where the affected lot may have been distributed.
What Product Is Being Recalled
According to the FDA announcement, the recall involves:
- Product name: Compounded Glutathione 200 mg/mL
- Form: 30 mL multi‑dose vials
- Type: Compounded injectable medication
- Scope: One identified lot, recalled to the patient level
The FDA notice identifies the product as a compounded drug. Compounded medications are custom-prepared by pharmacies for individual patients, typically when an approved drug does not meet a specific clinical need. In this case, the product is a high‑concentration glutathione solution intended for injection.
The FDA posting specifies that the recall is limited to a particular lot of this compounded glutathione product. The agency’s notice indicates that the recall extends down to patients, not only to pharmacies or clinics that may have purchased the vials.
How the Recall Is Being Carried Out
The FDA release states that Optimal Balance Pharmacy is conducting the recall voluntarily. In practice, a voluntary recall generally means the company has agreed to remove the affected product from the market in coordination with the FDA, rather than as the result of a formal enforcement action.
In its notice, the FDA describes the recall as nationwide, indicating that the affected lot may have been shipped to multiple states. The recall to the patient level means that the pharmacy and distributors are expected to notify not only health care facilities and prescribers, but also patients who may still have vials from the recalled lot in their possession.
The FDA posting explains that patients and health care providers who have the affected product should follow the recall instructions provided by Optimal Balance Pharmacy. Those instructions typically include stopping use of the recalled lot and arranging for its return or proper disposal. The FDA notice serves as a public alert to support that process.
Who Is Affected and What Patients Are Asked to Do
The FDA announcement states that the recall concerns patients and providers who received vials from the specific lot of Compounded Glutathione 200 mg/mL 30 mL multi‑dose vials prepared by Optimal Balance Pharmacy.
Because the recall is at the patient level and nationwide, the group potentially affected includes:
- Patients who were prescribed and received the recalled glutathione injectable from Optimal Balance Pharmacy or through their clinics
- Health care professionals who administer or dispense the product
- Facilities that store the product for ongoing treatment
The FDA notice advises that anyone in possession of the recalled lot should not continue to use it and should follow the recall instructions issued by the pharmacy. The agency’s posting indicates that patients with questions about their treatment should contact their health care provider, and that providers can consult the recall notice for details on how to identify the affected lot and what steps to take.
Why the Recall Matters
In its public communication, the FDA presents this recall as a safety‑related action involving an injectable compounded product. While the FDA notice centers on the recall itself rather than broader policy issues, it underscores several points that matter to patients and clinicians:
- Route of administration: The product is given by injection, which generally carries higher safety stakes than oral medications because it bypasses many of the body’s natural barriers.
- Compounded status: As the FDA notice makes clear, this is a compounded drug, prepared by a pharmacy rather than manufactured as an FDA‑approved finished product. Compounded drugs can play a role when approved options do not meet a patient’s specific needs, but they are also subject to quality and safety oversight.
- Scope of recall: The recall is nationwide and reaches down to patients, signaling that the affected lot may have been widely distributed and that people outside the Houston area could be using it.
The FDA’s publication of the recall is intended to help ensure that patients and providers are informed and can act quickly to remove the affected product from use.
What to Watch Next
The FDA notice states that Optimal Balance Pharmacy has already initiated the voluntary recall and that the action is underway. Patients and health care professionals are directed, through the FDA posting, to follow the instructions provided by the pharmacy for identifying and returning or disposing of the recalled lot.
Readers who believe they may have received Compounded Glutathione 200 mg/mL 30 mL multi‑dose vials from Optimal Balance Pharmacy can compare their product information with the details in the FDA recall notice and contact their prescriber or the pharmacy for guidance.
As of the information published in the FDA’s August 19, 2026 announcement, the central development is the initiation of this voluntary nationwide recall and the effort to remove the specified lot of compounded glutathione injectable from patient use.
